Table 3.
The 5-year overall survival (OS) and disease-free survival (DFS) rate in group after completion lymph node dissection (CLND) because of positive sentinel nodes according to clinical-pathological and molecular features of primary tumor and nodal metastases (calculated from the date of CLND)
| 5-year OS rate (95% confidence interval) | P value | 5-year DFS rate (95% confidence interval) | P value | |
|---|---|---|---|---|
| Primary melanoma Breslow thickness (mm) | ||||
| ≤1.0 | 77.8 (54.9–100) | .0001 | 39.6 (10.0–87.5) | .0001 |
| 1.01–2.0 | 68.6 (51.2–91.8) | 58.7 (40.9–84.4) | ||
| 2.01–4.0 | 60.5 (50.2–73.0) | 51.3 (41.0–64.2) | ||
| >4.0 | 38.7 (31.7–47.3) | 29.5 (23.0–37.7) | ||
| Ulceration of melanoma | ||||
| No | 66.8 (56.9–78.4) | <.0001 | 54.5 (44.5–66.7) | .0000 |
| Yes | 39.6 (32.7–47.9) | 29.0 (22.5–37.2) | ||
| Primary melanoma level of invasion according to Clark | ||||
| II–III | 57.6 (33.8–81.2) | .0083 | 48.5 (13.1–69.0) | .0009 |
| IV–V | 39.5 (27.5–56.8) | 28.5 (17.5–43.8) | ||
| Location of lymph node dissection | ||||
| Axillary | 42.6 (35.7–51.6) | .0098 | 34.1 (27.2–42.7) | .11 |
| Inguinal | 58.6 (50.0–68.7) | 44.7 (36.2–55.2) | ||
| Gender | ||||
| Female | 58.9 (51.2–67.7) | .0001 | 42.6 (35.1–51.8) | .04 |
| Male | 33.6 (25.6–44.1) | 29.1 (21.4–39.5) | ||
| Age (years) | ||||
| <40 | 58.2 (46.8–72.4) | .2054 | 48.6 (37.2–63.5) | .11 |
| 40–60 | 48.1 (33.9–62.5) | 34.8 (19.3–54.2) | ||
| ≥60 | 39.8 (17.4–63.5) | 35.4 (23.8–62.2) | ||
| Number of lymph nodes with metastases | ||||
| 1 | 59.6 (52.3–67.9) | <.0001 | 50.1 (42.7–58.8) | <.0001 |
| 2–3 | 36.5 (27.7–47.9) | 26.3 (18.6–37.2) | ||
| ≥4 | 29.3 (15.2–56.5) | 11.8 (3.7–38.0) | ||
| Extracapsular extension of lymph nodes metastases | ||||
| No | 53.5 (47.1–60.8) | <.0001 | 42.2 (35.9–49.6) | <.0001 |
| Yes | 26.9 (16.7–40.7) | 18.6 (10.8–32.2) | ||
| Metastases to additional non-SNs | ||||
| Absent | 55.9 (46.9–72.3) | .0004 | 48.7 (35.8–55.4) | <.0001 |
| Present | 32.5 (26.3–48.5) | 21.4 (12.5–37.2) | ||
| Maximal diameter of metastases to sentinel node | ||||
| <0.1 mm | 83.8 (58.3–100.0) | .0006 | 83.3 (58.3–100.0) | .004 |
| 0.1–1.0 mm | 66.2 (55.6–78.8) | 55.2 (44.5–68.5) | ||
| >1.0 mm | 40.2 (33.1–48.8) | 30.0 (23.5–38.4) | ||
| Microanatomic localization of metastases in SN | ||||
| Subcapsular | 43.6 (25.1–75.6) | .07 | 38.0 (21.7–66.3) | .2734 |
| Combined | 65.8 (52.6–82.2) | 42.0 (29.7–59.4) | ||
| Parenchymal | 59.5 (48.3–73.2) | 45.0 (33.7–60.0) | ||
| Multifocal | 39.4 (30.8–50.3) | 34.1 (26.0–44.9) | ||
| Extensive | 41.2 (28.1–60.3) | 26.5 (14.5–48.3) | ||
| Lymph MM RT-PCR assay result | ||||
| Positive | 46.7 (36.3–59.9) | .0007 | 39.0 (29.0–52.4) | .005 |
| Negative | 0 (NA–NA) | 21.1 (10.5–42.4) | ||
CLND group patients with regional lymph nodes metastases detected by sentinel lymph node biopsy followed by completion lymph node dissection, SN sentinel lymph node, MM RT-PCR multimarker reverse-transcriptase polymerase chain reaction, NA not available